Analyst Zhang Jialin from Nomura Securities wrote in a report that CSPC Pharma appears to benefit from the exclusive licensing agreement signed with Astrazeneca, aimed at developing and commercializing a preclinical lipid-lowering drug compound. The analyst pointed out that as part of the agreement, the pharmaceutical group will receive a prepayment of $0.1 billion. Zhang Jialin said: "Although it is too early to comment on the future of this compound, we are bullish on the impact of this deal on CSPC Pharma." The analyst added that the prepayment should allow CSPC Pharma to continue investing heavily in research and development. Nomura Securities maintains its buy rating on the stock with a target price of HKD 9.29.